Key PointsCRISPR Therapeutics is a potential home run if it can build on its Casgevy approval.One bad product has brought Zoetis to its knees -- but the selling is overdone.Danaher has slumped since the pandemic, but a recent acquisition could spark a rebound.10 stocks we like better than CRISPR Therapeutics › Long-term investing is about building your portfolio brick by brick. That could mean adding money weekly, monthly, or whenever you have e…